{"groups":[{"description":"During each 21-day cycle, participants received pembrolizumab 200 mg intravenously (IV) on Day 1 PLUS etoposide 100 mg/m\\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an area under the plasma drug concentration-time curve \\[AUC\\] 5 IV on Day 1 OR cisplatin 75 mg/m\\^2 IV on Day 1). Participants who stopped pembrolizumab as a result of obtaining a response of stable disease (SD), partial response (PR), complete response (CR) or those who stopped after receiving pembrolizumab for 24 months for reasons other than disease progression or intolerability, were eligible for up to an additional 1 year of treatment after progressive disease if they met the criteria for retreatment.","id":"FG000","title":"Pembrolizumab+EP"},{"description":"During each 21-day cycle, participants received placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m\\^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum therapy (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m\\^2 IV on Day 1).","id":"FG001","title":"Placebo+EP"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"195"},{"groupId":"FG001","numSubjects":"205"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"228"},{"groupId":"FG001","numSubjects":"225"}],"type":"STARTED"},{"achievements":[{"comment":"1 participant randomized to the pembrolizumab+EP arm was treated with placebo+EP.","groupId":"FG000","numSubjects":"223"},{"groupId":"FG001","numSubjects":"223"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Received Second Course of Pembrolizumab"},{"achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"200"},{"groupId":"FG001","numSubjects":"212"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"One participant who was randomized to the pembrolizumab+EP arm was inadvertently treated with placebo+EP. For efficacy analyses this participant will be included in the arm they were initially randomized into and for safety analyses the participant will be included by treatment received.","recruitmentDetails":"Participants in the pembrolizumab+ chemotherapy (etoposide/platinum \\[EP\\]) arm were eligible to receive second course treatment with pembrolizumab if they met criteria for re-treatment. Per protocol, response, progression, or patient reported outcomes during the second course were not counted towards efficacy outcome measures and adverse events during the second course were not counted towards safety outcome measures."}